Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell

• Male patients ≥ 18 years old

• Histologically verified metastatic germ cell cancer (GCC) of the testicle or extragonadal GCC originating from retroperitoneum or mediastinum

• Disease progression during cisplatin-based chemotherapy or Disease progression or relapse after high-dose chemotherapy or Disease progression or relapse after at least 2 different cisplatin-based regimens

• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-2

• Life expectancy ≥ 3 months

• At baseline adequate function of liver, kidneys and bone marrow:

⁃ ·Neutrophils ≥ 1.5 x 109/L·

• Hemoglobin ≥ 9.0 g/dL

• Platelets ≥ 100 x 109/L

• Creatinine ≤ 1.5 x upper limit of normal (ULN)

• Total Bilirubin ≤ 1.0 x ULN

• Serum glutamate oxaloacetate transaminase (SGOT/AST) ≤ 1.5 x ULN

• Serum glutamate pyruvate transaminase (SGPT/ALT) \< 1.5 x ULN